New approaches to management of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia

This paper addresses the background of phosphodiesterase-5 inhibitors use in erectile dysfunction and lower urinary tract symptoms, as well as a special position which is held by tadalafil as an only drug from its class suitable for daily intake. Tadalafil pharmacodynamics and hypotheses concerning...

Full description

Bibliographic Details
Main Authors: S. I. Gamidov, T. V. Shatylko, N. G. Gasanov, N. A. Naumov
Format: Article
Language:Russian
Published: ABV-press 2019-10-01
Series:Андрология и генитальная хирургия
Subjects:
Online Access:https://agx.abvpress.ru/jour/article/view/362
Description
Summary:This paper addresses the background of phosphodiesterase-5 inhibitors use in erectile dysfunction and lower urinary tract symptoms, as well as a special position which is held by tadalafil as an only drug from its class suitable for daily intake. Tadalafil pharmacodynamics and hypotheses concerning its mechanism of action on prostatic tissue are discussed. Special attention is paid to drug»s efficacy and safety in elderly men, who often require therapy for benign prostatic hyperplasia with lower urinary tract symptoms. It is mentioned that tadalafil may be used in penile rehabilitation programs in men who underwent radical prostatectomy.
ISSN:2070-9781